MedPath

The open-label study of the impact of dapagliflozin to the visceral fat for diabetes patients

Not Applicable
Conditions
Type 2 diabetes patients
Registration Number
JPRN-UMIN000017974
Lead Sponsor
Tokyo Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Dapagliflozin in use History of hypersensitivity to dapagliflozin containing components Severe ketosis diabetic coma or precoma Severe infection before and after surgery severe trauma

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
visceral fat
Secondary Outcome Measures
NameTimeMethod
clinical indicators abdominal circumference Hypoglycemia Body weight
© Copyright 2025. All Rights Reserved by MedPath